Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
127.52B
Market cap127.52B
Price-Earnings ratio
13.85
Price-Earnings ratio13.85
Dividend yield
3.99%
Dividend yield3.99%
Average volume
15.83M
Average volume15.83M
High today
$64.13
High today$64.13
Low today
$62.00
Low today$62.00
Open price
$63.22
Open price$63.22
Volume
15.87M
Volume15.87M
52 Week high
$68.64
52 Week high$68.64
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 127.52B, Bristol-Myers Squibb(BMY) trades at $62.45. The stock has a price-to-earnings ratio of 13.85 and currently yields dividends of 3.99%.

On 2026-09-30, Bristol-Myers Squibb(BMY) stock traded between a low of $62.00 and a high of $64.13. Shares are currently priced at $62.45, which is +0.7% above the low and -2.6% below the high.

Bristol-Myers Squibb(BMY) shares are trading with a volume of 15.87M, against a daily average of 15.83M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

BMY News

Simply Wall St 7h
What You Could Reuse From Bristol Myers Squibb's 46% Gain - simplywall.st

...

What You Could Reuse From Bristol Myers Squibb's 46% Gain - simplywall.st
TipRanks 10h
Bristol-Myers Squibb’s Real‑World Luspatercept Study Wraps Up, Setting the Stage for Next Growth Moves

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) has completed a real‑world study titled “Tre...

24/7 Wall St. 10h
Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric

Investing Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric Bristol Myers Squibb has raised its dividend for 17 straight ye...

Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric

Analyst ratings

58%

of 31 ratings
Buy
35.5%
Hold
58.1%
Sell
6.5%

More BMY News

Simply Wall St 2d
Why Is Bristol-Myers Squibb In Focus After New Phase 3 Myeloma Data?

Bristol-Myers Squibb (NYSE:BMY) reported the first Phase 3 EXCALIBER-RRMM results for ZENBEXUS in relapsed or refractory multiple myeloma. The pivotal trial sh...

Why Is Bristol-Myers Squibb In Focus After New Phase 3 Myeloma Data?
Simply Wall St 5d
What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders

In recent weeks, Bristol-Myers Squibb reported two-year Phase 3 POETYK PsA-2 data for Sotyktu in psoriatic arthritis, expanded access to ZENBEXUS through a rest...

What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders
TipRanks 6d
Bristol-Myers Squibb: Pipeline Uncertainties and Limited IPF Upside Lead Flynn to Reiterate Sell Rating and Maintain $40 Price Target

Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley maintained a Sell r...

TipRanks 6d
BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) has completed a Phase 1 study in China f...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.